1-4 of 4
Bryan Oronsky, MD
Close
Sort by
Journal Articles

Rrx-001 Is a Phase 3 Small Molecule Dual Inhibitor of CD47 and SirpĪ± with Activity in Multiple Myeloma

Pedro Cabrales, PhD, Corey Carter, MD, Bryan Oronsky, MD PhD, Tony Reid, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5623.
https://doi.org/10.1182/blood-2018-99-116947
Published: 2018
Journal Articles

Anti-Myeloma Activity of a Novel Free Radical Inducer Rrx-001

Deepika Sharma Das, PhD, Ze Tian, PhD, Arghya Ray, PhD, Durgadevi Ravillah, PhD, Yan Song, PhD, Paul G. Richardson, Bryan Oronsky, MD, Jan Scicinski, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2014) 124 (21): 4712.
https://doi.org/10.1182/blood.V124.21.4712.4712
Published: 2014
Journal Articles

Treatment with a Novel Dinitroazetidine, Abdnaz, Improves Nitrite Reductase Activity of Sickle Red Blood Cells

Marcel H.A.M. Fens, PhD, Sandra K Larkin, MS, William L Fitch, PhD, Jan Scicinski, PhD, Bryan Oronsky, MD, Frans A Kuypers, PhD
Journal: Blood
Blood (2012) 120 (21): 3246.
https://doi.org/10.1182/blood.V120.21.3246.3246
Published: 2012
Journal Articles

NO or No NO, Increased Reduction of Nitrite to Nitric Oxide by Modified Red Blood Cells

Marcel H.A.M. Fens, PhD, Sandra K Larkin, Claudia R. Morris, MD, Bill Fitch, PhD, Jan Scicinski, PhD, Bryan Oronsky, MD, Frans A Kuypers, PhD
Journal: Blood
Blood (2011) 118 (21): 2125.
https://doi.org/10.1182/blood.V118.21.2125.2125
Published: 2011